Sun Pharmaceutical Industries Ltd. closed 8.26% below its 52-week high of 1,885.00 rupees, which the company reached on ...

Sun Pharma's SPARC reduces workforce by 40%, consolidating operations and shifting to a hybrid research model for efficiency.

Sun Pharmaceutical Industries Ltd. closed 4.84% short of its 52-week high of 1,850.95 rupees, which the company achieved on May 2nd.

Across FY26–28, Jefferies forecasts double-digit revenue growth for the sector, led by Biocon (14%), boosted by upcoming ...

Natco’s escalates the legal battle over semaglutide, one of the world’s most valuable and closely contested pharmaceutical ...

They have also shared an outlook on pharma, telecom, internet platforms, banking, metals and consumer sectors, alongside ...

Indian pharmaceutical market (IPM) has registered a growth of 8.1 percent to touch ₹2,40,672 crore in 2025 and is likely to ...

Vishal Manchanda, Pharma Analyst at Systematix Group, said that when it comes to investing in the GLP-1 theme, the Indian ...

Indian drugmakers, known for their chemistry and prowess in making generics—cheaper copies of innovative drugs—for the world, ...

The US-Venezuela tensions has turned the spotlight on shares of companies like Indian Oil Corp, Oil India, Sun Pharma, Dr ...

Halvio Capital returned 5.62 percent this quarter while exploring international value opportunities. View our latest partner ...

The Indian Pharmaceutical Market (IPM) concluded 2025 with a valuation of approximately Rs 2,40,672 crore, reflecting a value growth of 8.1 per cent. According to the Pharmarack Indian Pharma Industry ...